Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 11/20 | 0.57 |
| ▸ | CNR2 | P34972 | 8/20 | 0.57 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1372681 | 0.86 | CNR1 (0.66) | CNR1CNR2PTGDR2KDM4ECYP1A2 | |
| Hydrochloric Acid SCHEMBL1373638 | 0.84 | CNR1 (0.65) | CNR1CNR2PTGDR2KDM4ECYP1A2 | |
| SCHEMBL19709884 | 0.78 | CNR1 (0.53) | CNR1CNR2KCNH2KMT2A | |
| SCHEMBL1373635 | 0.77 | CNR1 (0.65) | CNR1CNR2PTGDR2KDM4ECYP1A2 | |
| SCHEMBL1372532 | 0.74 | CNR2 (0.47) | CNR1CNR2 | |
| SCHEMBL1375392 | 0.73 | MAPT (0.51) | CNR1CNR2KDM4EMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL1376586 | 0.73 | CNR2 (0.46) | CNR1CNR2 | |
| SCHEMBL16236683 | 0.73 | CNR1 (0.57) | CNR1CNR2KCNH2 | |
| Hydrochloric Acid SCHEMBL1374910 | 0.73 | MAPT (0.50) | CNR1CNR2KDM4EMEN1KMT2A | |
| SCHEMBL3516336 | 0.72 | AHR (0.44) | CNR1CNR2KDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190160049-A1 | 2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE COMPOUNDS AND THEIR USE AS DUAL INHIBITORS OF PDK1/AURA | INTERNATIONAL SOCIETY FOR DRUG DEVELOPMENT S.R.L. (IT) | 2019-05-30 | — | — | US | disclosed |
| US-20190160049-A1 | 2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE COMPOUNDS AND THEIR USE AS DUAL INHIBITORS OF PDK1/AURA | INTERNATIONAL SOCIETY FOR DRUG DEVELOPMENT S.R.L. (IT) | 2019-05-30 | — | — | US | disclosed |
| EP-3468556-A1 | 2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE COMPOUNDS AND THEIR USE AS DUAL INHIBITORS OF PDK1/AURA | International Society for Drug Development S.r.l. (IT) | 2019-04-17 | — | — | EP | disclosed |
| WO-2017211946-A1 | 2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE COMPOUNDS AND THEIR USE AS DUAL INHIBITORS OF PDK1/AURA | INTERNATIONAL SOCIETY FOR DRUG DEVELOPMENT S.R.L. (IT) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017211946-A1 | 2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE COMPOUNDS AND THEIR USE AS DUAL INHIBITORS OF PDK1/AURA | INTERNATIONAL SOCIETY FOR DRUG DEVELOPMENT S.R.L. (IT) | 2017-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190160049-A1 | 2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE COMPOUNDS AND THEIR USE AS DUAL INHIBITORS OF PDK1/AURA | PDK1, PDK2, PDK3 | CNR1 2571/4885CNR2 1885/4885PTGDR2 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.